NEW YORK (GenomeWeb News) – Helicos BioSciences today said that it will raise net proceeds of roughly $9.4 million through the sale of its common stock and warrants to certain existing investors through a private placement.

The Cambridge, Mass.-based maker of single-molecule sequencing systems said that the investors include venture capital investors Atlas Ventures, Flagship Ventures, Highland Capital Partners, Versant Ventures, and the firm's CEO, Ron Lowy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.